Introduction
The involvement of the vascular endothelium in a large number of diseases which affect the vascular system, 1, 2 supports the importance of vascular-specific gene delivery for their treatment. An example of a vascular inherited disease is hereditary hemorrhagic telangiectasia (HHT). This is a dominant vascular disorder (OMIM 187300) associated with frequent epistaxis, telangiectases, gastrointestinal bleedings, and arteriovenous malformations (AVM) in the brain, lung and liver. [3] [4] [5] HHT is more common than previously estimated, with prevalence rates of one in 10 000, and age-related penetrance of over 90% by the age of 45. Manifestations develop throughout life and vary between affected individuals, even from the same family. This heterogeneity has been explained in part by the identification of two different gene loci. Endoglin is mutated in HHT1 and is associated with a high incidence of pulmonary AVMs, whereas mutations in the activin receptor-like kinase-1 (ALK-1) gene lead to HHT2, a milder form of the disease with a later onset. 4, 5 Endoglin is a homodimeric transmembrane glycoprotein highly expressed by endothelial cells. 6, 7 It is a transgenic animals which demonstrated endothelial expression of endoglin. Next, the promoters of the human endothelial genes, endoglin and ICAM-2, were inserted upstream of the human endoglin cDNA, and the resulting constructs were systemically or locally delivered, demonstrating endoglin expression in the vessel walls of liver, lung and skin. These gene transfer experiments represent an initial step in the treatment of the hereditary hemorrhagic telangiectasia type 1 by gene therapy, and suggest that endoglin and ICAM-2 promoters can be used to deliver other genes to the endothelium specifically. Gene Therapy (2001) 8, 897-904.
component of the transforming growth factor beta (TGF-␤) receptor complex as endoglin binds TGF-␤1, TGF-␤3, activin, BMP-2, and BMP-7; 8, 9 forms heterodimers with the TGF-␤ receptors types I and II 10, 11 and modulates cellular responses to TGF-␤1. [11] [12] [13] So far, more than 30 mutations have been reported in HHT1 patients, which affect the extracellular coding region of endoglin, generating premature stop codons. 4, 5 It has been postulated that HHT1 is originated by a mechanism of endoglin haploinsufficiency. [14] [15] [16] This hypothesis is supported by the finding in some heterozygous endoglin knockout animals, of vascular lesions similar to those present in HHT1 patients. 17, 18 Thus, it can be predicted that overexpression of the normal endoglin allele in endothelia might help in preventing vascular lesions in HHT1. Here, we demonstrate the in vivo expression of endoglin in the vasculature using human endothelial gene promoters, establishing the basis for a future application in gene therapy experiments.
Results
Analysis of transgenic mice A transgenic construct encoding the membrane-anchored human S-endoglin driven by the human ICAM-2 promoter was used to generate transgenic mice. Mice of two independent founder lines (30 and 34) were of the same size and weight as their non-transgenic littermates. They were fertile, showing a normal ratio of male to female littermates, had a normal lifespan, and had no specific susceptibility to disease (data not shown). Characterization of the transgene in the animals was carried out by Southern, Slot, and Western blot analyses (Figure 1 ). Enzymatic digestion of genomic and plasmid DNA with KpnI/SacI, followed by hybridization with a specific ICAM-2 probe allowed the identification of a 1.8-kb band corresponding to the transgene, as evidenced by Southern blot analysis (Figure 1a ). In addition, by comparing the levels of hybridization in slot blot analysis, heterozygous and homozygous animals could be distinguished (Figure 1b) . S-endoglin transgenic mice were able to express the membrane-bound human endoglin as demonstrated by Western blot analysis using a specific antibody ( Figure 1c) . As negative controls, samples from wild-type littermates were used in these assays.
Expression pattern of endoglin in transgenic mice
The expression of human endoglin was analyzed in several organs from adult transgenic mice. Formalin-fixed and paraffin-embedded sections of tissues taken from heterozygous offsprings of lines 30 and 34 of S-endoglin were stained with antibodies to human endoglin. Staining was found to be restricted to the vascular endothelium in all organs: large vessels and peritubular and glomerular capillaries in the kidney ( Figure 2a Gene expression pattern upon systemic delivery in vivo Similarly to the ICAM-2 promoter (Figure 2 ), transgene expression driven by the endoglin promoter has been detected in murine vascular endothelium of all organs examined. 19 Furthermore, the endoglin promoter displays tissue specific activity in cultured endothelial cells. 20, 21 The endothelial-specific gene expression driven by the ICAM-2 and endoglin promoters led us to assess whether these promoters could be used for in vivo gene delivery experiments. For this purpose, the ␤-galactosidase encoding constructs pd2/␤-Gal-N1, pICAM-2/␤-Gal, and pENDO/␤-Gal were mixed with a commercial carrier (TransIT; Panvera). The resulting mixture was intravenously injected into mice, 24 h later the animals were killed, and the ␤-galactosidase activity of the specific organs was determined ( Figure 3 ). ICAM-2 and endoglin promoter constructs were clearly active in lung, spleen, and liver, showing expression levels slightly lower than those of the cytomegalovirus-based construct. Overall, the pattern of activity of the three promoters was not paralleled among the different organs. This difference is probably due to the different tissue specificity of each promoter as well as to a different processing of the resulting transcripts. As a negative control, animals injected with carrier alone showed background levels of transgene expression. Also, a promoterless reporter plasmid yielded negligible levels of activity upon in vitro and 
Heterozygous transgenic S-endoglin mice of lines 34 (a, c-f) and 30 (b), as well as non-transgenic littermates (g-j), were perfused, and organs were fixed and paraffin embedded. Tissue sections from kidney (ac, g), spleen (d and h), lung (e and i), and liver (f and j) were stained with mAb SN6h (anti-endoglin) using an indirect immuno-peroxidase method. Samples were counterstained with hematoxylin. Panels a-f show expression of human endoglin (see arrowheads) at the lumen of the vessels, as evidenced by the brown staining of the peroxidase reaction using DAB as a substrate. Panels g-j show the negative controls from wild-type animals. Original magnifications: ×40 (a), ×100 (d, h, i), ×200 (b, e, f), and ×400 (c).
in vivo transfection (not shown), excluding a possible cryptic effect of the vector backbone. Next, we assessed whether endoglin expression could be targeted to the endothelium. For this purpose, the human endoglin expression vectors, pICAM-2/Endo-S and pENDO/Endo-S, were intravenously injected in vivo and the transfected tissues were stained with an antiendoglin antibody ( Figure 4 ). Specific expression of endoglin could be detected at the endothelium of the central vein in the liver (Figure 4a , b), and capillaries, medium vessels, and large arteries in the lung (Figure 4c, d ). In addition to endothelial cells, staining of isolated 
Figure 4 Immunohistochemical detection of endoglin upon systemic gene delivery in mice. Plasmids pICAM-2/Endo-S (a, c) or pENDO/Endo-S (b, d) were mixed with TransIT, and intravenously injected in mice. Animals were perfused and the transfected tissues fixed, paraffin embedded and stained with mAb SN6h (anti-endoglin). Endoglin was visualized (see arrowheads) by the brown staining of the peroxidase reaction using DAB as a substrate, (brown staining in a-c), or by the alkaline phosphatase reaction using Fast-Red as substrate (red staining in d) in tissue sections from liver (a, b) and lung (c, d). Central veins (a, b) in the liver, capillaries and medium vessels (c), and large arteries (d) in the lung were stained by the antibody. Original magnifications: ×200 (b); ×400 (a, c); ×1000 (d).
hepatocytes/Kupfer cells could be observed in the liver (data not shown), in agreement with the clearance role of this organ. 22 Taken together, these results demonstrate that both ICAM-2 and endoglin promoters can be used to deliver systemically gene expression in vivo.
Endoglin expression pattern upon local gene delivery Since vascular lesions in HHT1 are discrete and localized to specific organs (AVM in lung, liver and brain), or tissues (telangiectasia in skin and mucosa), we addressed the possibility of locally delivering endoglin. In addition, local delivery might serve to minimize possible undesired side-effects of systemic delivery. Intradermal injec-tions with pICAM-2/Endo-S and pENDO/Endo-S plasmids were carried out in mice and the transfected tissue was stained with anti-endoglin antibodies ( Figure 5 ). Specific expression of endoglin was demonstrated in the endothelium of small vessels present in the dermis, whereas nerve bundles were negative (Figure 5a ). Also, vessel walls of the subcutaneous tissue (Figure 5b , c) were clearly positive, in contrast to the negative staining of adipocytes (Figure 5b , c) and striated muscle ( Figure 5c ).
Next, local gene delivery was carried out into lung and liver of rats as these animals allow a more convenient surgical intervention than mice. Thus, Wistar rats were appropriately infused with pICAM-2/Endo-S and pENDO/Endo-S plasmids and endoglin expression was revealed by immunohistochemistry ( Figure 6 ). Both constructs yielded endothelial endoglin expression in the central vein (Figure 6a, b) , afferent sinusoids (Figure 6a) , and vessels of the portal system (Figure 6c, d ) of the liver, as well as in capillaries, small/medium vessels (Figure 6e , f, h), and large arteries (Figure 6g ) of the lung.
The histological sections from locally or systemically delivered plasmids were used to estimate the percentage of human endoglin-positive vessels ( Table 1) . The mean ± s.d. of immunoreactive vessels averaged percentages of 59-74% in local delivery experiments, whereas, the immunoreactive vessels in systemic experiments were in a lower range (37-40%). The highest efficiency of expression (over 70%) was obtained in the mouse skin using locally delivered constructs. Overall, no significant differences were observed between endoglin and ICAM-2 promoter constructs. These transfection efficiencies of the vasculature represent relative values, but they seem to be within the range of those previously reported. [23] [24] [25] These results indicate that local delivery of endoglin to skin, liver and lung endothelia can be performed with endoglin or ICAM-2 promoters.
Discussion
Targeted expression of genetic material to the vascular endothelium is potentially a powerful tool for both gene therapy and investigation of endothelial cell biology. Here, we have demonstrated endothelial gene expression using human endoglin and ICAM-2 promoters. These two promoters have been used to drive the expression of human endoglin, a gene mutated in HHT1. This disorder is characterized by frequent epistaxis and gastrointestinal hemorrhages associated with mucocutaneous telangiectasia in lips, fingers, tongue, ears, and conjuntivae. Other clinical manifestations include pulmonary, cerebral, and hepatic AVM, and less frequently spinal cord AVM. 3, 4 To the best of our knowledge, no gene delivery experiments have been reported to address the potential therapy of this disease. Thus, the tandem of human endoglin promoter and cDNA reported here is potentially an appropriate and physiological system to be used in correcting the haploinsufficiency of endoglin in HHT1. This synthetic gene delivery system avoids some of the disadvantages shown by the viral vectors, including the morbidity and mortality risks of viral infections, the oncogenesis induced by the viral genome, or the high, but unspecific expression of the gene of interest when using strong viral promoters. [26] [27] [28] While minimizing undesired side-effects, nonviral vectors display the drawback of relatively short a b c
Figure 5 Immunohistochemical detection of endoglin upon local gene delivery in mice. Plasmids pENDO/Endo-S (a, c) and pICAM-2/Endo-S (b) were mixed with TransIT, and intradermally injected in mice. Animals were perfused and the transfected skin was fixed, paraffin embedded, and stained with mAb SN6h (anti-endoglin). Endoglin was visualized (see arrowheads) by the peroxidase reaction using DAB as substrate (brown staining in panel b), or by the alkaline phosphatase reaction using FastRed as substrate (red staining in panels a and c). Some vessels were positively stained (a-c), in contrast to the negative staining of nerve bundles (n), adipocytes (a) and striated muscle cells (m). The unstained large vein in panel a, is probably a vessel which has not drained the DNA mixture and represents an internal negative control. Original magnifications:
×400. These are representative photomicrographs of three independent experiments performed with three different animals. Gene Therapy duration over viral vectors. However, the development of tissue-specific strategies, such as the one reported here, are allowing synthetic gene delivery to achieve optimal therapeutic effects. 27, 29 Thus, the use of its own promoter might lead to a more specific and regulated expression, as shown here for the endoglin gene. On the other hand, it would be interesting to explore the possibility of using the tandem of endoglin promoter/cDNA to transduce endoglin or other genes within a viral context. Potentially, this new viral system should display the advantage of high infection efficiency combined with endothelialspecific expression. Further studies are required to evaluate this possibility.
Figure 6 Immunohistochemical detection of endoglin upon local gene delivery in rats. Plasmids pICAM-2/Endo-S (a, c, e, g) and pENDO/Endo-S (b, d, f, h) were mixed with TransIT, and infused into rat liver and lung, as indicated in Materials and methods. Animals were perfused and transfected liver (a-d) and lung (e-h) tissues were fixed, paraffin embedded and stained with mAb SN6h (anti-endoglin). Endoglin was visualized (see arrowheads) by the peroxidase reaction using DAB as substrate (brown staining in panels a-e, g) or by the alkaline phosphatase reaction using Fast-Red as substrate (red staining in panels f and h). Endothelia from the central vein (a, b), sinusoids (a-c), and portal system (c, d) in the liver, as well as capillaries (e), small/medium vessels (e, f, h) and large arteries (g) in the lung were positively stained. Original magnifications: ×100 (c, f); ×200 (a, b, d, e, g, h). These are representative photomicrographs of four independent experiments performed with two different animals.
Endoglin and ICAM-2 promoters were able to express successfully endoglin upon local delivery in skin, lung, and liver. Treatment of vascular diseases by local gene therapy allows the delivery of therapeutic doses to target tissues while minimizing systemic side-effects. Therefore, skin and mucosa telangiectasia, as well as lung or liver arteriovenous malformations in HHT1, are potential therapeutic targets of the endoglin constructs described here. Interestingly, an endoglin knockout mice of the 129/Ola strain, but not of others, has revealed the existence of telangiectases and nosebleeds similar to those of HHT patients. 17 As in humans, only a subset of genetically predisposed animals display the vascular lesions. This and the strain-dependent susceptibility has led to the consideration of additional genetic and environmental precipitants of the full phenotype. 30 Future experiments will address the therapeutic or prophylactic potential of endoglin constructs in the animal model for HHT1.
The high and specific expression of endoglin in endothelial cells, together with several lines of evidence, support an important role for endoglin in vascular remodelling: (1) vascular lesions (telangiectasia and arteriovenous malformations) in endoglin haploinsufficient HHT1 patients are associated with a loss of the capillary network; 3 (2) mice lacking endoglin die in utero from defective vascular and heart development; 17, 18, 31 (3) antibodies to endoglin are able to modulate the angiogenic process in vivo; 32 and (4) augmented expression of endoglin has been detected in endothelia from neovascularized tissues such as in Graves' disease and Hashimoto's thyroiditis, 33 psoriasis, 34 ischemic stroke, 35 or tumors. [35] [36] [37] [38] [39] Therefore, apart from HHT1, targeting endoglin expression to the vasculature might be useful to study the pathologies listed above, which are associated with endoglin up-regulation, as well as to investigate the role of endoglin in the normal vascular physiology. Interestingly, the expression of endoglin in the tumor neovasculature has been used to design immunotoxins specific for endoglin as an anti-angiogenic treatment for solid tumors; 36, 40 it also suggests that the endoglin promoter could be used to deliver angiogenesis inhibitors in line with the proposed anti-angiogenic strategy to starve solid tumors. 41 Table 2 summarizes the plasmid constructs used throughout this study. The pICAM-2 plasmid, derived from the pBluescript II SK + vector, and containing the human ICAM-2 promoter, a universal intron, and down- 
Materials and methods Plasmids
stream polyadenylation signals, has been previously described. 42 The pICAM-2 vector was used to generate pICAM-2/Endo-S and pENDO/Endo-S constructs as follows. The pICAM-2/Endo-S vector containing the human S-endoglin isoform was obtained by digesting pCEXVEndo-S 43 with EcoRI, and the resulting 2.4-kb fragment of S-endoglin cDNA was inserted into the EcoRI site of the pICAM-2 vector. The pENDO/Endo-S vector was obtained by deleting the ICAM-2 promoter (338-bp NcoI/BamHI fragment) of the pICAM-2 vector followed by religation of the empty vector. The resulting vector was digested with KpnI/SalI and ligated with a 884-bp fragment obtained from a PCR amplification of the human endoglin promoter, 20 previously digested with KpnI/SalI. The amplification reaction was carried out using oligonucleotides A (5′-CGGGGTACCCCGCC ACTTTGGGACTTC-3′), containing a KpnI site, and B (5′-GCTATGGCCGACGTCGACGCGTGCTGTCCA-3′), containing a SalI site, and the endoglin promoter as a template, resulting in a fragment expanding positions −526 to +350.
20
The pd2/␤-Gal-N1 plasmid containing the Escherichia coli ␤-galactosidase gene driven by the cytomegalovirus promoter was obtained by cloning the 3.2-kb BamHI/XbaI fragment of ␤-galactosidase cDNA into the pd2EGP-NI vector (Clontech Laboratories, Palo Alto, CA, USA), previously digested with BamHI/XbaI to remove the sequence encoding the enhanced green fluorescence protein. The pICAM-2/␤-Gal vector encoding the ␤-galactosidase under the ICAM-2 promoter was obtained in a two-step process. First, the pd2/␤-Gal-N1 plasmid was digested with AsnI/NheI, the 583-bp insert containing the cytomegalovirus promoter was removed, and the vector religated. The resulting vector was digested with SalI/SacII and ligated with the 459-bp SalI/SacII fragment (ICAM-2 promoter) of the pICAM-2/Endo-S vector. The pENDO/␤-Gal vector encoding the ␤-galactosidase under the endoglin promoter was obtained as follows. The pd2/␤-Gal-N1 plasmid was digested with AsnI/NheI, the 583-bp insert containing the cytomegalovirus promoter was removed, and the vector religated. The resulting vector was digested with SalI/SacII and ligated with the 888-bp SalI/SacII fragment amplified by PCR from the endoglin promoter (positions −526/+350). The amplification reaction was carried out using oligonucleotides C (5′-ACGCGTCGACGTCAAACCACTTTGG GAC-3′), containing a SalI site, and D (5′-TCCCCGC GGGGAGCTGTCCACGT-3′), containing a SacI site, and the endoglin promoter as a template. 20 Transgenic mice Transgenic mice were generated by the Animal Biotechnology Service (Autonomous University, Barcelona, Spain). Basically, the pICAM-2/Endo-S transgenic plasmid was digested with BssHII and the resulting fragment of 3.7-kb was separated by agarose gel electrophoresis. The purified fragment was microinjected into fertilized C57BL76xSJL mouse embryos and transferred into pseudopregnant CD1 mice. Progeny was screened for transgene copy number and integrity by slot and Southern blot analyses. Blots were hybridized with a 32 Plabeled probe generated by digestion of the pICAM-2/Endo-S vector with KpnI/SacI/BamHI resulting in a 375-bp ICAM-2 promoter fragment. Southern blot analysis of KpnI/SacI digested genomic DNA revealed a 1.8-kb band upon binding with the specific probe.
Systemic gene delivery experiments
Systemic transfections of pd2/␤-Gal-N1, pICAM-2/␤-Gal, pENDO/␤-Gal, pICAM-2/Endo-S and pENDO/ Endo-S constructs were performed using TransIT polyamine (Panvera, Madison, WI, USA) according to the manufacturer's protocol. Basically, Swiss female mice (5-6 weeks old weighing 25 g) were intravenously injected with 50 g of DNA (at a ratio of 1 g of DNA/l of TransIT polymer) in a single bolus through the tail vein using a 27-gauge needle. When using naked plasmid DNA, the highest protein expression levels are usually obtained 10-24 h after injection. 44 Thus, mice were killed 24 h after injection, and lung, liver, and spleen were removed. For ␤-galactosidase experiments, organs were minced, lysed with 100 mm potassium phosphate pH 7.8 and 0.2% Triton X-100, and enzymatic activity was measured using a chemiluminescent reporter gene assay (Galacto-Light Plus, Tropix, Bedford, MA, USA). The recombinant ␤-galactosidase enzymatic activity was corrected for the endogenous ␤-galactosidase activity of the corresponding tissues from non-transfected animals. For transfections of human endoglin constructs, organs were fixed in 4% buffered formalin, dehydrated, embedded in paraffin, and subjected to immunohistochemical analysis.
Local gene delivery experiments
Gene delivery was also targeted to the mouse skin and to the rat liver and lung. Local transfections into the skin were carried out by a single intradermal injection in the abdomen of Swiss mice with 5 g of DNA (at a ratio of 1 g of DNA/l of TransIT polymer) in a final volume of 200 l. For gene delivery into liver and lung, 4-monthold male Wistar rats were anesthetized with 2-2-2 tribromoethanol. For liver transfection, a small left subcostal incision was performed, the spleen was exposed and punctured with a PE-50 catheter, as previously reported. 45 For lung transfection, the right jugular vein was exposed and catheterized with a PE-20 catheter, whose tip was advanced to the right atria. In both cases, 5 g of DNA (at a ratio of 1 g of DNA/l of TransIT polymer) in a final volume of 0.5 ml was slowly infused for 3-5 min.
Animals were killed 24 h after injection, and the transfected tissues were removed, fixed in 4% buffered formalin, dehydrated, embedded in paraffin, and processed for immunohistochemical detection of endoglin.
All experimental protocols involving animals were performed according to the European Community guidelines (86/609 and 98/81).
Immunohistochemistry
Tissues were fixed in 4% buffered formalin. In some cases, anesthetized mice were perfused with PBS through the right cardiac ventricule, and fixed by immersion in 4% buffered formalin during 24 h. After dehydration, pieces were embedded in paraffin and 3 m sections were cut and mounted on glass slides. Tissue sections were stained with mAb SN6h, which is specific for an epitope within the fragment E26-G230 of human endoglin 46 and can be used for formalin-fixed tissues (DAKO Diagnosticos, Barcelona, Spain). Samples were processed using either an avidin-biotin complex immunoperoxidase method (ABC Staining System, Santa Cruz Biotechnology, CA, USA), or an alkaline phosphatase kit (BioGenex Laboratories, San Ramon, CA, USA). The presence of endoglin was revealed using either 3,3′-diaminobenzidine (DAB) as substrate of the peroxidase, or FastRed as substrate of the alkaline phosphatase. Samples were counterstained with hematoxylin. Endoglin labeling was examined by microscopy using a Zeiss Axiovert 135 microscope (Zeiss, Oberkochen, Germany). For statistical analysis, the number of positive and negative immunoreactive vessels was determined in 75-100 different fields from at least five different preparations using a high powered magnification (×400).
Western blot analysis
Liver, lung, kidney, or heart from transgenic or control mice were excised, minced in 10 mm Tris, 150 mm NaCl containing a protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany), and sonicated in microcentrifuge plastic tubes. All manipulations were carried out at 4°C. Samples were incubated for 45 min, and non-disrupted tissues were discarded by spin down at 600 g for 10 min. Disrupted materials were pelleted, washed twice by centrifugation at 14 000 g for 15 min, resuspended in solubilization buffer (1% NP-40, 10 mm Tris, 150 mm NaCl, and a protease inhibitor cocktail), and the resulting soluble fractions were used in Western blot analysis. For this purpose, equal amounts of total protein were subjected to SDS-PAGE on 6% polyacrylamide gels under reducing conditions. Proteins were electrophoretically transferred to nitrocellulose membranes (Millipore, Bedford, MA, USA). Filters were blocked with PBS containing 5% milk powder for 1 h. Specific immunodetection was carried out by incubation overnight at room temperature with mouse mAb P4A4, which recognizes an epitope within the fragment Y277-G331 of human endoglin electrophoretically separated under reducing conditions. 47 Then, filters were incubated with peroxidase-conjugated rabbit anti-mouse Ig and the presence of endoglin was revealed using a chemiluminescence assay (ECL detection kit; Amersham Ibérica, Madrid, Spain).
